Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group.
about
Chemotherapy for advanced non-small cell lung cancer in the elderly populationSecond or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseOptimal duration of chemotherapy for advanced non-small cell lung cancerOptimal duration of chemotherapy for advanced non-small cell lung cancerSecond or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseA comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancerGemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study.Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.Gemcitabine and carboplatin combination chemotherapy for elderly patients with advanced Non-Small Cell Lung Cancer: a feasibility study.[A meta analysis of gemcitabine plus platinum chemotherapy compared with single-agent chemotherapy in the treatment of non-small cell lung cancer].A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.A phase II study of first-line chemotherapy with weekly carboplatin plus gemcitabine in advanced non-small cell lung cancer.Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in Treatment of Advanced Non-small Cell Lung Cancer: A Randomized Clinical Trial.Combination of low-dose gemcitabine in 6-hour infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small cell lung cancer.Doublets versus single-agent therapy as first-line therapy for elderly patients with advanced non-small cell lung cancer? A systematic review of randomised controlled trials.Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapyEltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I studyClinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials.Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II StudyHealth-related quality of life in advanced non-small cell lung cancer: correlates and comparisons to normative data.Molecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancerPulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.What is the role of maintenance therapy in the treatment of non-small cell lung cancer?Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials.Surgical treatment of stage IV non-small cell lung cancer.Chemotherapy in Patients Older than or Equal to 75 Years with Advanced Non-small Cell Lung CancerEfficacy and safety of chemotherapy for newly diagnosed advanced non-small cell lung cancer with venous thromboembolismGemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer.EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population.Optimal pharmacotherapeutic strategies for elderly patients with advanced non-small cell lung cancer.Factors affecting efficacy and safety of add-on combination chemotherapy for non-small-cell lung cancer: a literature-based pooled analysis of randomized controlled trials.Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuation.Effect of chemotherapy on quality of life in patients with non-small cell lung cancer.A review of the management of elderly patients with non-small-cell lung cancer.Pharmacotherapy for treatment of lung cancer in the elderly.Use of the lung cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in clinical trials: A systematic review of the literature 20 years after its development.Interstitial lung disease associated with gemcitabine: A Japanese retrospective cohort study.Specific Safety Profile of Bevacizumab in Asian Patients With Advanced NSCLC: A Meta-Analysis.Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.Saudi lung cancer management guidelines 2017.
P2860
Q24186466-1CFFB4AA-D79C-4131-B47F-F2B6FFFF1FC2Q24200518-291461D3-688C-495C-A4F0-EEBB363365A2Q24200970-6EFE2497-CE37-46D6-8C6A-21C61802B6EFQ24242409-0750A89C-B8C1-4F4A-BC2B-166109B7A387Q24243664-D4C670CF-5ACB-491C-82D8-0B65D747BD42Q26865662-CCD79581-3653-442A-88CF-BAFA65F389BCQ33373188-D555C76D-664F-4CB0-9713-252DFFDE0F84Q33375704-F633D00E-741C-42CA-95B7-39D89462EB26Q33385869-915E51B8-7D71-4994-B13E-B565A63AF9C8Q33391099-F469903A-0126-4153-8D21-A8940058786AQ33392085-305522EA-79A4-46DE-869B-01E25ACBCBF3Q33399989-AD15AA50-4A87-4596-838C-34E015EC33BDQ33405558-5F3E3604-D47C-4A92-B456-468275E5390AQ33410610-E019895E-89D7-4A37-A8D6-60426453B69BQ33411167-A2AF7721-ECAC-4D0F-8937-E9CB5BA541E0Q33417019-78A2BF94-1173-491C-B5EA-EB11834BC222Q33417372-F07E876F-921B-48C4-BA1E-1625F9174B01Q33430977-D2C4893A-A6C4-4191-ACA7-EF872253D7A3Q33516118-66A27067-FAB0-490C-98CE-7CCD12819461Q34240483-09C95744-CAF3-42E4-9E7E-B33EC8ED74E6Q34243500-3B914112-308D-4374-B29A-AF0B86D823F2Q34626688-34AC91FF-7FAC-4784-979F-A01E919CCAF6Q35076269-13B8A0D7-F61C-4EE7-99F2-07AAEF8EF8D5Q35111780-AD8F65B5-7228-44A9-8C54-90506B3D4DD8Q35758398-77D95E40-6EF2-4A88-8FF6-79EC5E6D75F6Q35877754-3D2239AC-97B9-4313-95F3-0C5D9135642EQ36247897-F3D7A4A2-431D-4943-BA79-ABDB8295427FQ37013079-7D50A997-5F30-42E3-B620-D8D89A300455Q37589341-43309287-BD17-4BAD-A57B-E0FE847D5637Q37952852-F10ADCA9-62F5-47E8-A7C3-E1D3078FC361Q37986608-6AB670B5-C398-463C-9E8E-A446F85C816AQ37992189-71BA5279-1969-47F0-90BD-266E6E6818AEQ38190461-DFAC8F2F-BD55-47DE-9AE9-D9790BA98235Q38233740-4A3393A6-AD59-42EE-8E3B-C492EE246FA4Q38386745-9C9A1F0B-59DA-45BF-AEC4-A96401E813D1Q38602994-4FCFFA49-927D-4BEB-AAAA-142BAF6F698CQ40099115-B0FB1211-E6FD-4FB9-9B91-655D6562A45DQ41656758-A2ACC240-D953-483E-BB5E-80DC6A6434E3Q43973311-F4E5FECB-E933-49D9-9E79-C7BD9F0C004DQ47096145-5F2D1B1A-BF0E-4DAE-90E2-A1D1E4B5032E
P2860
Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Phase III trial of gemcitabine ...... edish Lung Cancer Study Group.
@ast
Phase III trial of gemcitabine ...... edish Lung Cancer Study Group.
@en
type
label
Phase III trial of gemcitabine ...... edish Lung Cancer Study Group.
@ast
Phase III trial of gemcitabine ...... edish Lung Cancer Study Group.
@en
prefLabel
Phase III trial of gemcitabine ...... edish Lung Cancer Study Group.
@ast
Phase III trial of gemcitabine ...... edish Lung Cancer Study Group.
@en
P2093
P356
P1476
Phase III trial of gemcitabine ...... edish Lung Cancer Study Group.
@en
P2093
Christer Sederholm
Gunnar Hillerdal
Karl Kölbeck
Kristina Lamberg
Monika Dufmats
Ronny Westberg
Sulochana R Gawande
P304
P356
10.1200/JCO.2005.01.2781
P407
P577
2005-11-01T00:00:00Z